ReP USP - Resultado da busca

Artigo de periodico
Antineoplastic effects of pharmacological inhibitors of aurora kinases in CSF3R^T618I-driven cells (2024)
Parducci, Natalia Sudan ; Garnique, Anali Del Milagro Bernabe ; Lima, Keli Cristina de ; Carlos, Jorge Antonio Elias Godoy ; Fonseca, Natasha Peixoto ; Miranda, Lívia Bassani Lins De ; Almeida, Bruna Oliveira de ; Rego, Eduardo Magalhães ; Traina, Fabiola ; Machado Neto, João Agostinho
Source: BLOOD CELLS MOLECULES AND DISEASES. Unidades: FMRP, ICB, FM
Subjects: PROTEÍNAS QUINASES, ANTINEOPLÁSICOS, BAINHA DE MIELINA, MUTAÇÃO GENÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PARDUCCI, Natalia Sudan et al. Antineoplastic effects of pharmacological inhibitors of aurora kinases in CSF3R^T618I-driven cells. BLOOD CELLS MOLECULES AND DISEASES, v. 104, 2024Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/58756. Acesso em: 18 nov. 2024.
APA
Parducci, N. S., Garnique, A. D. M. B., Lima, K. C. de, Carlos, J. A. E. G., Fonseca, N. P., Miranda, L. B. L. D., et al. (2024). Antineoplastic effects of pharmacological inhibitors of aurora kinases in CSF3R^T618I-driven cells. BLOOD CELLS MOLECULES AND DISEASES, 104. doi:10.1016/j.bcmd.2023.102799
NLM
Parducci NS, Garnique ADMB, Lima KC de, Carlos JAEG, Fonseca NP, Miranda LBLD, Almeida BO de, Rego EM, Traina F, Machado Neto JA. Antineoplastic effects of pharmacological inhibitors of aurora kinases in CSF3R^T618I-driven cells [Internet]. BLOOD CELLS MOLECULES AND DISEASES. 2024 ; 104[citado 2024 nov. 18 ] Available from: https://observatorio.fm.usp.br/handle/OPI/58756
Vancouver
Parducci NS, Garnique ADMB, Lima KC de, Carlos JAEG, Fonseca NP, Miranda LBLD, Almeida BO de, Rego EM, Traina F, Machado Neto JA. Antineoplastic effects of pharmacological inhibitors of aurora kinases in CSF3R^T618I-driven cells [Internet]. BLOOD CELLS MOLECULES AND DISEASES. 2024 ; 104[citado 2024 nov. 18 ] Available from: https://observatorio.fm.usp.br/handle/OPI/58756
Artigo de periodico
NT157 exerts antineoplastic activity by targeting JNK and AXL signaling in lung cancer cells (2022)
Miranda, Lívia Bassani Lins De ; Lima, Keli Cristina de ; Silva, Juan Luiz Coelho ; Traina, Fabiola ; Kobayashi, Susumu S. ; Machado Neto, João Agostinho
Source: Scientific Reports. Unidades: FMRP, ICB, FM
Subjects: FARMACOLOGIA, NEOPLASIAS PULMONARES, ANTINEOPLÁSICOS, NEOPLASIAS PULMONARES, ANTINEOPLÁSICOS, CÉLULAS CULTIVADAS DE TUMOR, ONCOGENES, TRANSDUÇÃO DE SINAL CELULAR, PROTEÍNAS PROTO-ONCOGÊNICAS, PROTEÍNAS QUINASES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MIRANDA, Lívia Bassani Lins De et al. NT157 exerts antineoplastic activity by targeting JNK and AXL signaling in lung cancer cells. Scientific Reports, v. 12, p. 1-11, 2022Tradução . . Disponível em: https://doi.org/10.1038/s41598-022-21419-6. Acesso em: 18 nov. 2024.
APA
Miranda, L. B. L. D., Lima, K. C. de, Silva, J. L. C., Traina, F., Kobayashi, S. S., & Machado Neto, J. A. (2022). NT157 exerts antineoplastic activity by targeting JNK and AXL signaling in lung cancer cells. Scientific Reports, 12, 1-11. doi:10.1038/s41598-022-21419-6
NLM
Miranda LBLD, Lima KC de, Silva JLC, Traina F, Kobayashi SS, Machado Neto JA. NT157 exerts antineoplastic activity by targeting JNK and AXL signaling in lung cancer cells [Internet]. Scientific Reports. 2022 ; 12 1-11.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1038/s41598-022-21419-6
Vancouver
Miranda LBLD, Lima KC de, Silva JLC, Traina F, Kobayashi SS, Machado Neto JA. NT157 exerts antineoplastic activity by targeting JNK and AXL signaling in lung cancer cells [Internet]. Scientific Reports. 2022 ; 12 1-11.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1038/s41598-022-21419-6
Artigo de periodico
NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia (2021)
Ribeiro, Renata Scopim ; Machado Neto, João Agostinho ; Eide, Christopher A. ; Silva, Juan Luiz Coelho da ; Fenerich, Bruna Alves ; Fernandes, Jaqueline Cristina; Scheucher, Priscila Santos ; Stevens, Samantha L. Savage ; Campos, Paula de Melo; Saad, Sara T. Olalla ; Palma, Leonardo de Carvalho ; Pontes, Lorena Lobo de Figueiredo ; Simões, Belinda Pinto ; Rego, Eduardo Magalhães ; Tognon, Cristina E. ; Druker, Brian J. ; Traina, Fabiola
Source: Investigational New Drugs. Unidades: ICB, FMRP, FM
Subjects: FARMACOLOGIA, LEUCEMIA MIELOIDE, INSULINA, ANTINEOPLÁSICOS, PROTEÍNAS QUINASES, CÉLULAS SANGUÍNEAS, PROLIFERAÇÃO CELULAR, APOPTOSE, ONCOGENES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RIBEIRO, Renata Scopim et al. NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. Investigational New Drugs, v. 39, n. 3, p. 736-746, 2021Tradução . . Disponível em: https://doi.org/10.1007/s10637-020-01028-8. Acesso em: 18 nov. 2024.
APA
Ribeiro, R. S., Machado Neto, J. A., Eide, C. A., Silva, J. L. C. da, Fenerich, B. A., Fernandes, J. C., et al. (2021). NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. Investigational New Drugs, 39( 3), 736-746. doi:10.1007/s10637-020-01028-8
NLM
Ribeiro RS, Machado Neto JA, Eide CA, Silva JLC da, Fenerich BA, Fernandes JC, Scheucher PS, Stevens SLS, Campos P de M, Saad STO, Palma L de C, Pontes LL de F, Simões BP, Rego EM, Tognon CE, Druker BJ, Traina F. NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia [Internet]. Investigational New Drugs. 2021 ; 39( 3): 736-746.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1007/s10637-020-01028-8
Vancouver
Ribeiro RS, Machado Neto JA, Eide CA, Silva JLC da, Fenerich BA, Fernandes JC, Scheucher PS, Stevens SLS, Campos P de M, Saad STO, Palma L de C, Pontes LL de F, Simões BP, Rego EM, Tognon CE, Druker BJ, Traina F. NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia [Internet]. Investigational New Drugs. 2021 ; 39( 3): 736-746.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1007/s10637-020-01028-8
Artigo de periodico
PIP4K2A and PIP4K2C transcript levels are associated with cytogenetic risk and survival outcomes in acute myeloid leukemia (2019)
Lima, Keli Cristina de ; Silva, Juan Luiz Coelho da ; Kinker, Gabriela Sarti ; Pereira-Martins, Diego Antonio; Traina, Fabiola ; Fernandes, Pedro Augusto Carlos Magno ; Markus, Regina P ; Lucena-Araújo, Antonio Roberto Lucena; Machado Neto, João Agostinho
Source: Cancer Genetics. Unidades: FMRP, IB, ICB, FM
Subjects: LEUCEMIA MIELOIDE, LIPÍDEOS, CITOGENÉTICA, PROTEÍNAS QUINASES, LIPÍDEOS, TRANSCRIÇÃO GÊNICA, MICRORNAS, EXPRESSÃO GÊNICA, RNA, GENÔMICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LIMA, Keli Cristina de et al. PIP4K2A and PIP4K2C transcript levels are associated with cytogenetic risk and survival outcomes in acute myeloid leukemia. Cancer Genetics, v. 233-234, p. 56-66, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.cancergen.2019.04.002. Acesso em: 18 nov. 2024.
APA
Lima, K. C. de, Silva, J. L. C. da, Kinker, G. S., Pereira-Martins, D. A., Traina, F., Fernandes, P. A. C. M., et al. (2019). PIP4K2A and PIP4K2C transcript levels are associated with cytogenetic risk and survival outcomes in acute myeloid leukemia. Cancer Genetics, 233-234, 56-66. doi:10.1016/j.cancergen.2019.04.002
NLM
Lima KC de, Silva JLC da, Kinker GS, Pereira-Martins DA, Traina F, Fernandes PACM, Markus RP, Lucena-Araújo ARL, Machado Neto JA. PIP4K2A and PIP4K2C transcript levels are associated with cytogenetic risk and survival outcomes in acute myeloid leukemia [Internet]. Cancer Genetics. 2019 ; 233-234 56-66.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.cancergen.2019.04.002
Vancouver
Lima KC de, Silva JLC da, Kinker GS, Pereira-Martins DA, Traina F, Fernandes PACM, Markus RP, Lucena-Araújo ARL, Machado Neto JA. PIP4K2A and PIP4K2C transcript levels are associated with cytogenetic risk and survival outcomes in acute myeloid leukemia [Internet]. Cancer Genetics. 2019 ; 233-234 56-66.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.cancergen.2019.04.002

USP Schools

ReP

Filtros

Authors

USP affiliated authors

Subjects

Funding Agencies

Indexado em

Non normalized affiliation